Buy HIMS by Nov 18, 2025.

**TL;DR:** Investors are pulling back from pharmaceutical stocks as RFK Jr. has been appointed to lead HHS, creating an opportunity for $HIMS stock while it is still undervalued. If RFK pushes to block Medicare/Medicaid coverage of costly anti-obesity drugs like Ozempic, Wegovy, and Zepbound, people could turn to more affordable alternatives like $HIMS. In 2022, Medicare alone spent over $4.6 billion on Ozempic, and that number likely ballooned in 2023/2024. As RFK targets big pharma, affordable GLP-1 drugs from $HIMS …